Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.64 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.54 |
| ▸ | BTK | Q06187 | 3/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.41 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31605518 | 0.93 | AR (0.65) | ARCRBNBTKDDB1IKZF3 | |
| SCHEMBL31605511 | 0.93 | AR (0.65) | ARCRBNBTKDDB1IKZF3 | |
| SCHEMBL31605508 | 0.90 | AR (0.63) | ARCRBNBTKDDB1IKZF3 | |
| SCHEMBL31605498 | 0.90 | AR (0.63) | ARCRBNBTKDDB1IKZF3 | |
| SCHEMBL31605536 | 0.90 | AR (0.63) | ARCRBNBTKDDB1IKZF3 | |
| SCHEMBL29597385 | 0.88 | CRBN (0.55) | ARCRBNBTKDDB1IKZF3 | |
| SCHEMBL20046202 | 0.86 | AR (0.57) | ARCRBNBTKDDB1IKZF3 | |
| SCHEMBL20046199 | 0.84 | AR (0.57) | ARCRBNBTKDDB1IKZF3 | |
| SCHEMBL23134592 | 0.84 | CRBN (0.56) | ARCRBNBTKDDB1IKZF3 | |
| SCHEMBL22661504 | 0.84 | AR (0.54) | ARCRBNBTKDDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025108404-A1 | HETEROCYCLIC COMPOUND OF BIFUNCTIONAL CHIMERA FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND USE THEREOF | 广东东阳光药业股份有限公司 | 2025-05-30 | — | — | WO | disclosed |
| US-20240409529-A1 | Methods of Manufacturing a Bifunctional Compound, Ultrapure Forms of the Bifunctional Compound, and Dosage Forms Comprising the Same | ARVINAS OPERATIONS, INC. (US) | 2024-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409529-A1 | Methods of Manufacturing a Bifunctional Compound, Ultrapure Forms of the Bifunctional Compound, and Dosage Forms Comprising the Same | PAICS, UGT1A1, PBRM1 | AR 1243/4885CRBN 1606/4885BTK 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.